Novo Nordisk (NVO) & Eli Lilly (LLY) | Asset Consensus | Yatirim Radar | Yatırım Radar

Menu

Agenda Radar Daily Digest My Watchlist

Markets Assets Consensus Signals Economic Calendar

Analysts Compare Analysts

Sectors Themes Ideas Screener

Smart Score Compare Asset Relations

Changes Seasonal Analysis Category Rotation

Video Impact Forgotten Picks Coverage Gaps My Analytics Community Pulse

📱Mobile App

Your radar, pocket-sized

Real-time alerts, Premium checkout, and the full experience on mobile.

App Store Google Play

Loading...

Not investment advice under CMB regulations. Every analysis links to its source and is reviewed by editors. Methodology ·

© 2026 Yatırım Radar. All rights reserved.

About Us Methodology Masthead FAQ Blog Privacy Policy Terms of Service Contact

Agenda Radar Daily Digest My Watchlist Markets Assets Consensus Signals Economic Calendar Analysts Compare Analysts Sectors Themes Ideas Screener Smart Score Compare Asset Relations Changes Seasonal Analysis Category Rotation Video Impact Forgotten Picks Coverage Gaps My Analytics Community Pulse Blog Premium

Yatırım Radar

Catch Opportunities on Your Radar

Novo Nordisk (NVO) & Eli Lilly (LLY) | Asset Consensus | Yatirim Radar | Yatırım Radar

AssetsNovo Nordisk (NVO) & Eli Lilly (LLY)Analysis

NOV

Asset · Weak Signal

Novo Nordisk (NVO) & Eli Lilly (LLY)

Price unavailable1 calls · 0+ analysts · last 90 days

Radar Score

Weak Signal

Radar profile

5-factor impact analysis

Coverage, strength, recency, conviction and momentum.

Factor notes

Detailed grading

No analyses found yet.

Consensus history

How recommendation distribution changed over time

Strong BuyBuyHoldSellStrong Sell

Not enough data to chart consensus history.

Recommendation distribution

1 total calls

Strong Buy0 · %0

Buy0 · %0

Hold0 · %0

Sell0 · %0

Strong Sell0 · %0

Recommendation timeline

Chronological view of analyst calls on this asset

Newest calls at the top.

Feb 18, 20262 months ago
BuybyMarty MakaryCNBC Television
The speaker evaluates the active pharmaceutical ingredient (API) supply processes in the GLP-1 drug market and the role of sector leaders in approved manufacturing standards.

Recent analyses

Recent calls on Novo Nordisk (NVO) & Eli Lilly (LLY)

Novo Nordisk (NVO) & Eli Lilly (LLY)

International Stocks

Buy

The speaker evaluates the active pharmaceutical ingredient (API) supply processes in the GLP-1 drug market and the role of sector leaders in approved manufacturing standards.

MM

Marty Makary

CNBC Television

64d

Price Chart + Analyst Markers

No price data available for this asset.